HK Stock Market Move | ANTENGENE-B(06996) increases by more than 14%. The company plans to increase investment in research and development of AI drugs. XEVIOR is approved for launch in Indonesia.

ANTENGENE-B (06996) rose more than 14%, with a year-to-date increase of 390%. As of the time of writing, it had increased by 14.18% to 3.22 Hong Kong dollars, with a trading volume of 14.96 million Hong Kong dollars. In terms of news, Deqi Medicine announced yesterday that the Indonesian Food and Drug Administration (BPOM) has approved the market application (NDA) of XPO1, a new drug. XPO1 is the world's first novel mechanism oral selective XPO1 inhibitor, which has been approved for the treatment of multiple indications in 10 countries and regions in the Asia-Pacific market, and has been included in medical insurance in 5 markets (Mainland China, Taiwan, Australia, Singapore, and South Korea). In addition, based on its unique mechanism of action, the company is developing multiple combination therapies of XPO1 in different disease areas such as myelofibrosis (MF) and endometrial cancer. It is worth mentioning that in February of this year, Deqi Medicine announced plans to increase investment and integrate resources to establish a dedicated AI department. This initiative includes the local deployment of DeepSeek to accelerate the research and development of the next generation pipeline of T-cell engagers (TCE) with spatial hindrance shielding effects. It is reported that the company had already invested in the Hangzhou Derui Intelligent Medicine AI drug discovery platform as an angel investor in 2021, strategically entering the field of AI drug discovery. The company has also successfully discovered a new liver cancer-related tumor antigen (TAA) through AI data model combined with multi-omics analysis, and developed it into a TCE candidate drug entering the preclinical validation stage.